Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Acrivon Therapeutics, Inc. - Common Stock (NQ:ACRV)

1.870 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6
Open 1.870
Bid (Size) 1.880 (100)
Ask (Size) 1.920 (2,000)
Prev. Close 1.870
Today's Range 1.870 - 1.870
52wk Range 1.050 - 8.000
Shares Outstanding 21,925,982
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
On Friday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill

Performance

YTD
-24.0%
-24.0%
1 Month
-22.7%
-22.7%
3 Month
N/A
N/A
6 Month
+41.7%
+41.7%
1 Year
-66.2%
-66.2%

More News

Read More
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session. ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
News headline image
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Friday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Acrivon Posts Narrower Loss in Q2 ↗
Via The Motley Fool
News headline image
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga

Frequently Asked Questions

Is Acrivon Therapeutics, Inc. - Common Stock publicly traded?
Yes, Acrivon Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Acrivon Therapeutics, Inc. - Common Stock trade on?
Acrivon Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Acrivon Therapeutics, Inc. - Common Stock?
The ticker symbol for Acrivon Therapeutics, Inc. - Common Stock is ACRV on the Nasdaq Stock Market
What is the current price of Acrivon Therapeutics, Inc. - Common Stock?
The current price of Acrivon Therapeutics, Inc. - Common Stock is 1.870
When was Acrivon Therapeutics, Inc. - Common Stock last traded?
The last trade of Acrivon Therapeutics, Inc. - Common Stock was at 01/15/26 04:00 PM ET
What is the market capitalization of Acrivon Therapeutics, Inc. - Common Stock?
The market capitalization of Acrivon Therapeutics, Inc. - Common Stock is 41.00M
How many shares of Acrivon Therapeutics, Inc. - Common Stock are outstanding?
Acrivon Therapeutics, Inc. - Common Stock has 41M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.